Perfood

Perfood

Wellness and Fitness Services

Prescription digital therapeutics powered by personalized nutrition.

About us

Reimagining medicine At Perfood, we translate state-of-the-art data and medical science into therapy. We create software, that precisely identifies what actions need to be take on a personalized level, to prevent or fight diseases. Using sensors, lab results and holistic analyses, we derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. We call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects. We believe that our genetic heritage is an elementary compound of our health. But we also believe that much more than our predisposition, our everyday actions determine whether we stay healthy or get sick. Among all triggers – activity, breezing or sleeping – we believe that nutrition is the leading factor. Our digital therapeutics are all rooted in our proprietary technology for personalized nutrition. Vast kinds of food deliver various nutrients that are processed directly by the human body, but also by microbes that live in a symbiotic relationship with us. Understanding these complex processes is our passion. Translating these processes into effective therapy is our mission. In 2017, we pioneered research on personalized nutrition at the leading German life science University of Lübeck. In 2018 we launched the first scientific personalized nutrition program for wellness and weight management. In 2020, we invented a completely novel way of treating migraine with sinCephalea, a digital therapy powered by personalized stable-glycemic nutrition. On our journey, we have built an exceptional pipeline of digital therapeutics with our proprietary technology at its foundation. With a powerful deep phenotyping dataset, we unveil the interception of disease and develop the most effective healthcare solutions, combining diagnostics and precision treatments. We welcome you to join us on this ride.

Industry
Wellness and Fitness Services
Company size
11-50 employees
Headquarters
Lübeck
Type
Privately Held
Founded
2017

Locations

Employees at Perfood

Updates

  • Excellent news from Perfood CMO Torsten Schröder, MD, PhD and our R&D Team. Let's keep ambitions high. ⛑️

    View profile for Torsten Schröder, MD, PhD, graphic

    Chief Medical Officer & Founder @Perfood - Helping to envision and develop cutting-edge digital therapeutics with personalized nutrition as an active ingredient

    🎉 Exciting Milestone Achieved! 🎉 Last Patient in 🎉 We’re thrilled to announce that the last patient has been enrolled in our groundbreaking digital therapeutic trial for diabetes – the largest of its kind in the industry! 🌟 This effort marks a major step toward transforming diabetes management through the cutting-edge #glucura #DiGA solution. With more than 320 patients taking part in this innovative trial, we’re one step closer to reshaping how patients take control of their health. A heartfelt thank-you to our dedicated team, visionary partners, and, most importantly, the participants who made this possible. Together, we’re paving the way for innovation and improved outcomes in diabetes care. Stay tuned for updates as we move forward in this exciting chapter of research and discovery. The future of diabetes care is digital – and it’s happening now.

  • Innovative Strategies in Diabetes Management Spotlighted at Wismar Diabetes Day Today, the 18th annual Wismar Diabetes Day is taking place. Healthcare professionals, researchers, and policymakers are discussing advancements in the management of #diabetes, with a special emphasis on diabetic neuropathy and the integration of digital therapeutics into patient care. ➡️ Personalized Approaches to Diabetes Care Kicking off today’s sessions, Prof. Stefan Zimny of Helios Klinikum Schwerin will present modern diagnostic and therapeutic strategies for diabetic neuropathy, a condition that poses significant challenges within the broader spectrum of diabetes management. ✅ Embracing Digital Innovation Another highlight will be Perfood CMO Torsten Schröder, MD, PhD and a team from the University of Lübeck sharing the latest developments in digital therapeutics (DiGAs) for type 2 diabetes. The presentation will show how these innovative digital tools are being tailored to improve lifestyle management and patient outcomes through precise, personalized interventions. ⛑️ Addressing Systemic Challenges Federal states such as Mecklenburg-Vorpommern (MV) are important to develop the discussion around integrating DiGAs into formal healthcare. As far back as 2008, health leaders recognized the shortage of healthcare professionals posed risks in providing adequate levels of healthcare for people in MV. What was also important was the proactive stance taken by The Association of Statutory Health Insurance Physicians in Mecklenburg-Vorpommern (KVMV), which commissioned the study. Among potential solutions explored was e-health. Today, DiGAs stand as a testament to what can be achieved to alleviate the challenges faced by federal states such as MV. Not only do DiGAs reduce the amount of direct human resources needed for healthcare, DiGAs also provide validated and approved therapeutic interventions, health data organized for effective communication with health professionals and accessibility regardless of how small or large the community in which people are living in. DiGAs may be new and much work is needed to build a strong understanding of their value among healthcare professionals - but DiGAs solve important problems we have already identified, some of which are becoming more critical. This is why our team at Perfood and stakeholders from the University of Lübeck see participating in events such as today's in Wismar as essential in helping to solve critical challenges in healthcare - in places such as MV but in reality, in many, many parts of Germany. Innovations such as #DiGAs put people at the center of improving their health. Now the job is putting our collective effort to making DiGAs successful - for patients, for our society and for the financial stability of our healthcare system.

    • Chief Medical Officer of Perfood, Dr. med. Torsten Schröder will speak today at the 18. Wismarer Diabetestag. 

Highlighting the day's innovative spirit, Dr. Schröder, in collaboration with colleagues from the University of Lübeck, will share insights from their development of a prescription digital therapeutic (DiGA) for type 2 diabetes. This session is particularly anticipated for its promise to demonstrate how cutting-edge digital tools can integrate into traditional treatment frameworks to enhance lifestyle management and patient outcomes.
  • View organization page for Perfood, graphic

    2,797 followers

    Perfood achieves clinically relevant advance in the management of migraine It has long been recognized that there are significant challenges around the care for people suffering from migraines. In 2009, Prof. Dr. med. Arne May, the then President of the German Migraine and Headache Society (#DMKG) noted that there were insufficient doctors and specialists to address the needs of those who endure the severe burdens and disabilities stemming from migraines. Said Dr. May to the Hamburger Abendblatt: “There are still too few doctors who specialize in the treatment of migraine, too few inpatient and day-care services, too slow a transfer from research to practice and too little implementation of the guidelines for the treatment of these diseases.” Let's now fast forward. In 2023, the Ärzte Zeitung published an article on the “Updated guideline on the treatment and prevention of migraine”. In that article, it was noted that non-drug therapies for migraine were important and should not be ignored: “Overall, it should be noted that not only medication should be used for acute treatment and prophylaxis, emphasized PD Dr. Gudrun Gossrau, Dresden. The guideline also contains new recommendations in this regard. A comprehensive approach consisting of drug and non-drug therapy options is important for good pain management, added PD. Dr. Stefanie Förderreuther, Munich. (ba)” These critical objectives have always driven us in developing an innovative therapy for migraine that would benefit patients; but not only patients, also healthcare professionals and the healthcare system as a whole. This week, Perfood is announcing a significant milestone in helping people who endure episodic migraines. Our abstract, entitled: "Digital Approaches in Migraine Management: Evaluating the Efficacy of sinCephalea, a Prescription Digital Therapeutic" will be shared at the European Headache Congress in Rotterdam. We support and believe in the motto of the #EHC: “Towards a better headache treatment for everyone.” And in that vein, we share the conclusion in the abstract, which is based on the data in our Randomized Controlled Trial (#RCT): ✅ Our study demonstrates the efficacy of the DTx sinCephalea. It is the first prophylactic therapy using #CGM influencing glycemic variation to reduce #migraine frequency. This novel approach represents a clinically relevant advance in the management of migraine. Perfood is committed to the mission of helping to achieve a new era in the treatment options for people with migraine - and we thank everyone who has helped us to achieve this milestone. Among them: PROF. DR. DR. STEFAN EVERS Hanna C.B. Grube Astrid Gendolla Priv.-Doz. Dr. med Charly Gaul Dr. Kristian Ewald, MHBA Oliver Witt Dr. Jenny Voggel PD Dr. med. Matthias Nitschke Christian Sina Prof. Dr. med. Diamant Thaci Univ.-Prof. Dr. rer. biol. hum. Inke R. König Torsten Schröder, MD, PhD We look forward to sharing more news about #sinCephalea with you.

    • Photo showing PROF. DR. DR. STEFAN EVERS. Prof. Evers is a specialist in neurology. He is also a key opinion leader for the DiGA firm, Perfood GmbH, based in Lübeck, Germany. Perfood has developed a DiGA for episodic migraine and Prof. Evers is the lead author for the paper based on the Randomized Control Trial that has been undertaken as part of the requirements for the permanent approval of sinCephalea. Prof. Evers will be at the European Headache Congress 2024 in Rotterdam to interact with other experts and discuss the results of the analysis for sinCepahalea. The abstract is entitled: "Digital Approaches in Migraine Management: "Evaluating the Efficacy of sinCephalea, a Prescription Digital Therapeutic"
  • Celebrating Collaboration on World Diabetes Day On September 15, 1925, Frederick Grant Banting shared the monumental journey to isolate insulin and begin using it clinically during his Nobel Lecture. Banting acknowledged a diverse and extensive group of contributors who played pivotal roles in this discovery—from colleagues at the Toronto General Hospital to global researchers - and of course, Charles H. Best. What Banting emphasized was not just the scientific breakthrough but the collaborative spirit that made it possible. Today, as we face ongoing challenges in diabetes care, this ethos of cooperation remains more relevant than ever. Innovations in diabetes treatment continue to be driven by a worldwide network of researchers, physicians, and technologists. This World Diabetes Day, let's recommit to this spirit of collaboration. By working together across disciplines and borders, we can forge ahead with solutions that manage, prevent, and ultimately aim to cure diabetes. Join us in honoring those who have contributed to this cause and support ongoing efforts that promise a healthier future. Let us celebrate by acknowledging the collective efforts that drive progress in diabetes care. Just in case, here is Banting's Nobel Lecture: https://lnkd.in/gQvbt6tj #WorldDiabetesDay #DiabetesCare #HealthInnovation

  • Transforming Diabetes Care: The Power of Collaboration and Digital Innovation This weekend, Berlin will host a seminal event that stands at the convergence of tradition and innovation in diabetes care—the "Meilensteine der modernen Diabetologie 2024" (Milestones in Modern Diabetology). This year, the event not only commemorates World Diabetes Day but also marks a pivotal moment for healthcare professionals, patients, and technology providers in the diabetes community. At Perfood, we are proud to sponsor and participate in this significant event, where our Chief Medical Officer, Torsten Schröder, MD, PhD, will contribute to the vibrant discussions aimed at enhancing diabetes management through digital therapeutics and real-world evidence. Torsten will contribute to the discussion entitled: "Mit Leichtigkeit zum Leichtgewicht? - was dürfen wir von Abnehmmedikation, personalisierter Ernährungsberatung, DIGAs und CGM erwarten?" ("With Ease to Lightweight? - what can we expect from weight loss medication, personalized nutrition counseling, DIGAs, and CGM?"). This discussion will explore the multifaceted approaches to diabetes management - especially the connection between obesity and diabetes. A key pillar for effective diabetes treatment is personalization. In this regard, DiGAs for type 2 diabetes such as our own glucura come into focus as they utilize data from CGMs to provide individualized nutrition guidance. Additionally, the application of artificial intelligence enhances the therapy by offering data-driven guidance in simple and achievable steps, helping individuals make sustainable progress. Underlining the contribution that our DiGA glucura can make in this immense challenge, Torsten says:, "glucura offers a personal compass. Affected individuals can take control of their diabetes themselves. Achievable goals each week are important, as learning in small steps is much more effective." We invite all stakeholders—from medical professionals and researchers to policymakers and patients—to join us in Berlin. Together, we can push the boundaries of what's possible in #diabetes care through open dialogue and collaborative efforts. The event is organized by diabetesDE - Deutsche Diabetes-Hilfe and entry is free. All the details you need are here: https://lnkd.in/ejhVi-PT

    Für ein besseres Leben für Menschen mit Diabetes.

    Für ein besseres Leben für Menschen mit Diabetes.

    meilensteine-diabetologie.de

  • A Conversation We feel a sense of honor and responsibility when people are interested in the challenges we are tackling at Perfood. Recently, the former minister of health for the state of Schleswig-Holstein, Dr. Heiner Garg stopped in for an informal visit. Dr. Garg spoke with CEO Dominik Burziwoda and spent time in the guts of our operations, where the CGM sensors and therapy kits are carefully put together and sent out to people facing the challenges of type 2 diabetes and migraines. While a visit may seem to many like just a small occurrence in the humdrum of a startup, it is in fact much more. Innovation cannot be sustained and cannot succeed without open and robust conversations. In fact, it may be as important as the science, technology, and product development that must take place to actually change the course of the diseases that affect millions of people, and our economic prosperity. In the case of Dr. Garg, he knows firsthand that effective healthcare begins with a clear and open understanding. In fact, even before he was a health minister and FDP leader in Schleswig-Holstein, he wrote a paper entitled: 📎 ‘The need for care as an object of economic security policy’ ("Pflegebedürftigkeit als Gegenstand ökonomischer Sicherungspolitik"). This focus on the importance of the big picture in healthcare is critical. As a startup, the path to effectively integrating our innovations and products into the healthcare system is not straightforward — and we don’t expect it to be. Healthcare is about people, and as such requires oversight and the contributions of many stakeholders. This is an attitude we fully embrace. When we look at just the challenges around diabetes and the scale of the response needed, we see how much we can contribute to this immense priority. This mission is what drives us. In the case of Dr. Garg, perhaps another reason he was curious about us as a digital therapeutics and DiGA company is that he was at the epicenter of the COVID-19 pandemic response in Schleswig-Holstein. He knows intimately that there needs to be a strong capacity to innovate and, in some instances, do it as quickly as we can think. As Dominik Burziwoda always points out, in the area of prescription digital therapeutics, Germany has a once-in-a-century opportunity to be the definitive leader in this emerging sector. But in pursuing this lofty goal, we know that the most important part of what we have to do is to have open, collaborative, and productive conversations with all stakeholders. We may not always see the problems and solutions in the same way, but with openness and conversation, we are confident we will always find the path forward. So while this was just a short visit from someone who has seen and contributed to addressing some of the biggest health challenges of our time, we see it as a model of what will make German innovation in healthcare a success story — an open conversation. #germany #healthcare #innovation

    • A glimpse into the recent visit by Dr. Heiner Garg, former Minister of Health for Schleswig-Holstein, to Perfood GmbH in Lübeck, Germany. 

In these images, Dr. Garg engages deeply with our CEO, Dominik Burziwoda, discussing the nuances of our innovative approach to managing type 2 diabetes and migraines through digital therapeutics. 

The visit underscores our commitment to impactful healthcare solutions and highlights the collaborative spirit necessary to drive forward medical innovation. 

Join us in this journey as we work together to transform the landscape of healthcare.
    • No alternative text description for this image
    • No alternative text description for this image
  • The results of an important study supported by Perfood is the focus of an article just published E-HEALTH-COM. This study demonstrated significant reductions in HbA1c levels - and body weight - among participants using Perfood’s #DiGA, glucura. What is notable in the article is the focus on the foundations of the effectiveness of our approach in real-world settings. At the heart of glucura is our proprietary artificial intelligence (#AI ) system, which works seamlessly with continuous glucose monitoring (#CGM) technology to analyze glucose data. This AI component is predictive, which means glucura can tailor dietary and lifestyle recommendations that evolve with the user’s needs. By learning from daily glucose fluctuations and correlating them with user input on food intake and physical activity, our AI provides actionable insights that are not only based on historical data but are also predictive of future trends, enhancing the efficacy of diabetes management. As noted by the author of the article: ‘… the AI “learns” about the individual patient’s metabolism and then abstracts longer periods from this. The app provides highly individualized lifestyle recommendations beyond the limited CGM period…’ This leads to the question, ‘can an app such as glucura replace weight loss injections?’ While we see it positively that glucura is being looked at in this way, our CEO Dominik Burziwoda makes an important observation. At end of the day, the most effective solution for type 2 diabetes are people themselves and what is done over a longer period of time. 💬 Says Dominik: “… the real miracle cure is the people affected themselves, because long-term success can only be achieved if they change their lifestyle - with or without weight loss injection.” This is why we have put so much effort into the design of glucura - for it to be, in a sense, like a trusted companion that results in substantial and lasting changes in tackling type 2 diabetes. We look forward to sharing more about glucura with you. You can also find the study published in Journal of Diabetes Science and Technology entitled:  ➡️ Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic here: https://lnkd.in/eFkTQgJr And thank you to Philipp Grätzel von Grätz, Chefredakteur E-HEALTH-COM for taking an in-depth look at glucura and the study related to its effectiveness. Here is the link to his article: https://lnkd.in/eUWMgSB4 #perfood #diabetes #DiGA

    Diabetes-App statt Abnehmspritze?

    Diabetes-App statt Abnehmspritze?

    e-health-com.de

  • Breakthrough Migraine Management: Insights from ARD's 'Buffet' At Perfood, we put tremendous effort into science, research and product development. The truth is though, the value of all of this is diminished if there isn’t a wider discussion about how people can use these products to live without the burden of chronic diseases. And this is why we value tremendously when shows such as ARD’s 'Buffet' are interested and motivated to share the story of how people can address chronic health challenges with something they do every day – food and nutrition. Recently, in an episode of 'Buffet,' viewers were introduced to a groundbreaking treatment for migraine that could potentially transform millions of lives. Perfood's DiGA, sinCephalea. The segment wove together the personal journey of Isabell Morgenstern, who found substantial relief from her migraines with sinCephalea, and a wider discussion on the connection between glucose regulation and migraines. The episode included expert insights from well-known nutritionist and author, Achim Sam. Sam explained the connection between eating, glucose regulation and migraines. Migraines affect millions globally. Research and studies from Perfood show that one of the keys to alleviating the intense discomfort caused by migraines lie in our daily diet—specifically, how our bodies react to glucose. The segment explores this approach, showcasing how stabilizing glucose levels can significantly reduce migraine occurrences. This episode doesn’t merely recount a success story; it delves deep into the science behind migraines and dietary influences. Viewers get to see a thoughtful discussion on the physiological processes involving glucose fluctuations and their impacts on migraine symptoms, making complex medical concepts accessible and engaging. Discussions such as this one on ARD do a tremendous public service by introducing a wider audience to innovative #DiGA apps, which Germany is leading the way in developing, and which are paving the way for a new era in healthcare. You can watch the full episode here: https://lnkd.in/e3GBh-y7

    ARD-Buffet: Sendung vom 05.09.2024 - hier anschauen

    ARD-Buffet: Sendung vom 05.09.2024 - hier anschauen

    ardmediathek.de

  • The European Association for the Study of Diabetes (EASD) conference is in full swing in Madrid. The European Association for the Study of Diabetes e.V. (EASD) is an important forum for improving approaches to caring for people with diabetes. It supports groundbreaking diabetes research and promotes the next generation of leading diabetes researchers across Europe. This makes it a key platform for collaboration and innovation in diabetes care and management. The influence of the EASD in setting standards for diabetes therapy is also significant. This headline from 2018 in Practice Nurse stands out to us. "New guideline transforms approach to therapy in T2D: New consensus guidance from the American Diabetes Association and European Association for the Study of Diabetes offers a dramatic shake-up of the conventional order of glucose lowering drugs, with newer agents given more prominent 'ranking'." Another notable theme at the EASD historically has been the integration of information technology in diabetes care. Of course, research and developing patient-centric and effective solutions to diabetes is also a critical focus for us at Perfood. This year, we are thankful that we are adding to the collective knowledge in cutting edge approaches to treating people with type 2 diabetes. An important research paper supported by Perfood has been published in Journal of Diabetes Science and Technology. It is entitled: "Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic." In this groundbreaking study, 118 participants with non-insulin-treated Type 2 diabetes utilized Perfood's #DiGA, glucura for three months. The results are promising: ❗ Improved Blood Sugar Control: On average, participants saw a 0.67% reduction in their HbA1c levels, a key marker of long-term blood sugar control. For those with poorly controlled diabetes, the improvement was even more significant — a 1.08% reduction compared to standard care. ❗ Greater Success in Reaching Therapeutic Targets: The percentage of patients achieving an HbA1c level below 7.0% jumped from 38% to 60%. Remarkably, 33% of participants were on their way to diabetes remission, with HbA1c levels dropping below 6.5%. ❗ Sustained Benefits: For participants who continued using glucura for six months, the benefits only grew. They experienced further reductions in HbA1c and an average weight loss of 6.84 kg. If you would like to know more about the details of the results from this study, our CMO Torsten Schröder, MD, PhD is in Madrid. You can reach out to him on LinkedIn or send a note to ts@perfood.de And here is the link to the paper in the Journal of Diabetes Science and Technology: https://lnkd.in/eFkTQgJr Sending lots of well wishes to all of the participants at the 2024 EASD conference.

    • The image shows Perfood GmbH chief medical officer, Torsten Schröder signing a document at the University of Lübeck.

Schröder is an author - along with others of a new paper entitled: "Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic".

This is a big step in showing that artificial intelligence along with continuous glucose monitoring (CGM) can help to improve therapy for people with type 2 diabetes.

Schröder is in Madrid at the 2024 European Association for the Study of Diabetes conference to talk to people about Perfood and the work we are doing to advance the treatment of type 2 diabetes.
  • A Vision for the Future of Digital Health We at Perfood are thrilled to share that our co-founder and CTO, Dr. med. Christoph Twesten, has now joined the board of the Spitzenverband Digitale Gesundheitsversorgung (SVDGV). In his new role, Christoph is championing an essential balance that resonates deeply with our core mission: enhancing data protection while maximizing the utility of data in prescription digital health therapeutics. Christoph believes passionately that 'finding a good balance between data protection and data usage for digital health solutions, and strengthening trust in new technologies like AI, are fundamental. Because when such products are designed securely, they can deliver significant added value to our care.' Join us in congratulating Christoph as he continues to influence the digital health landscape by focusing on ensuring safe and effective solutions that benefit patients. Congratulations dear Christoph. #Perfood #DigitalHealth #DataProtection #AI #HealthcareInnovation

    Unsere Reihe erreicht heute ein Ende und das letzte Vorstandsmitglied stellt sich vor 👋 Mein Name ist Dr. med. Christoph Twesten und ich bin Mitgründer und CTO der Perfood GmbH. 🔒 Im Vorstand des #SVDGV sorge ich für Sichtbarkeit der Themen #Datenschutz, Datensicherheit und #Interoperabilität und leite im Verband auch den AK Datenschutz. Als gelernter #Mediziner und Mitgründer eines DiGA-Herstellers bringe ich außerdem diese beiden Perspektiven ein. ♥️ Besonders am Herzen liegt mir, wie wir für digitale Gesundheitslösungen eine gute Balance zwischen Datenschutz und Datennutzung finden und dass wir Vertrauen in neue Technologien, wie jetzt KI, stärken. Denn wenn solche Produkte sicher konzipiert sind, können sie einen erheblichen Mehrwert für unsere Versorgung liefern. 🗓️ Als SVDGV-Vorstand möchte ich in diesem Jahr vor allem die technische #Sicherheit digitaler Lösungen im Verband fördern und vorantreiben sowie das Vertrauen und Verständnis für digitale Therapien und KI in der Medizin voranbringen. #digitalversorgt #svdgv #vorstellungsrunde #vorstand

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Perfood 2 total rounds

Last Round

Series unknown
See more info on crunchbase